Revumenib Citrate Patent Expiration
Revumenib Citrate was first introduced by Syndax Pharmaceuticals Inc
Revumenib Citrate Patents
Given below is the list of patents protecting Revumenib Citrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Revuforj | US10683302 | Inhibitors of the menin-MLL interaction | Jun 08, 2037 | Syndax |
| Revuforj | US11479557 | Inhibitors of the menin-MLL interaction | Jun 08, 2037 | Syndax |
Revumenib Citrate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List